Swiss pharmaceutical giant Roche will be offering two of its expensive cancer drugs at reduced prices in India in order to gain a strong foothold in the market.
The decision comes close on heels of rival Bayer losing out its exclusive rights to produce kidney cancer drugs in the country with the Indian government deciding that generic and cheaper versions of the drug will be produced locally in order to make sure that a large section of patients have access to the drugs.
Lung Cancer Screening
Lung cancer accounts for nearly 1.3 million deaths annually worldwide. Lung cancer screening can help in early detection of cancer and possible cure.
Advertisement
Roche has denied that its decision to offer it two cancer drugs, Herceptin and MabThera, was based on Bayer losing out its exclusive rights with a Roche spokesman stating that it was the company's strategy to work along with the governments of the emerging markets.
"It is part of our overall strategy in emerging markets, where we work closely with governments and payers in order to enable access to our medicines. With this strategy, we expect to significantly increase the number of patients treated with our therapies and help patients currently under treatment to continue to use our products properly", the spokesman said.
Source: Medindia
Source: Medindia
Pap smear and Cervical Cancer Screening
Pap smear is the most common test used in screening cervical cancer caused by an infection with human papilloma virus. Pap smear should be repeated every 1 to 3 years till the age of 65 years.
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Cancer News
Improved oral health, as indicated by the count of natural teeth and dental appointments preceding the diagnosis, correlated with enhanced head and neck cancer survival rates.
The presence of painless swelling in the lymph nodes could potentially indicate lymphatic cancer, say experts.
Women tested at high risk for breast cancer using non-clinical genetic tests overlooking family history may decide to undergo unnecessary breast surgery.
Atezolizumab-bevacizumab drug combination can yield positive outcomes in terms of extended survival and the elimination of liver cancer.
Reflux disease manifests as acid regurgitation and heartburn and is a known risk factor for esophageal cancer.
